Recruiting

Quercefit® & Ubiqsome™The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

Sponsor:

Applied Science & Performance Institute

Code:

NCT07760506

Conditions

Healthy Aging

Inflammaging

Metabolic Health

Quercetin

Coenzyme Q10

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Interventions

Quercetin (dietary supplement)

Coenzyme Q10

Rice Flour

Study Details

Brief summary:

The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.

The main questions it aims to answer are:

1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo?
2. What side effects, if any, do participants have while taking these supplements?

Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient).

Participants will:

1. Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks
2. Go to a preferred clinic at the start and end of the study for a fasting blood draw

Complete at-home tests:
3. Grip strength testing (using a device mailed to them)
4. Online surveys about fatigue and quality of life
5. Report any side effects and keep track of supplement use

Conditions

Healthy Aging

Inflammaging

Metabolic Health

Quercetin

Coenzyme Q10

Study ID

NCT07760506

Start date

Sep 18, 2026

Status verified date

Sep, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Aug, 2028

Anticipated

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

Males and females aged 50 to 75 years
Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).
BMI of > or equal to 25.00kg/m²
Individuals with > or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
Free of all other chronic diseases.
Not currently using glucose-lowering agents or insulin.
Able to read and write in English
Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.
During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.
During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements
Willing to have blood drawn
Must have access to a reliable internet connection and a computer to complete remote assessments

Exclusion Criteria:

Unwilling to have blood drawn
Unwilling to swallow pills
Pregnancy or has breast fed within 3 months prior to enrollment
Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months
Current use of Quercetine or CoQ10 supplements within the past 4-weeks
History or current alcohol or drug abuse
Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.
Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B/C, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment
Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)
History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)
History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)
History of kidney or liver disease
History of metabolic disorders (diabetes, metabolic syndrome, other)
History of current malignancy/cancer
Receiving chemotherapy agents or radiation treatments
Diagnosis of a terminal illness
The investigator feels that, for any reason, the subject is not eligible to participate in the study

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Group 1 (Quercefit® only)

500 mg Quercefit® per day, administered as one 250 mg capsule taken twice daily (morning and evening)

active comparator: Group 2 (Ubiqsome™ only)

300 mg Ubiqsome™ per day, administered as one 150 mg capsule taken twice daily (morning and evening)

placebo comparator: Group 3 (Placebo)

One placebo capsule taken twice daily (morning and evening)

Interventions

Quercetin (dietary supplement)

Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.

Coenzyme Q10

Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.

Rice Flour

An inert carbohydrate used as the control treatment

Primary outcome measure

Inflammaging (CIMKDM) [ Time Frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90) ]
Phenotypic Age [ Time Frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90) ]

Central Contacts and Locations

Central contacts

Tony Zavala, BS

8138678888 tzavala@theaspi.com

Gabe Wilson, PhD

8136738888 gwilson@theaspi.com

Locations

The Applied Science and Performance Institute

Recruiting

Tampa, Florida, United States, 33634

Contacts

Gabe Wilson, PhD

8136738888 gwilson@theaspi.com

Eric Sikorski, PhD

8136738888 eskiorski@theaspi.com

Principal Investigator:

Jacob Wilson, PhD

More Information

Sponsor

Applied Science & Performance Institute

Last update posted

Sep 17, 2026

Last verified

Sep, 2026

Keywords

Healthy Aging
Inflammaging
Metabolic Health
Blood testing
Pre-Diabetic
Composite Inflammaging Metric
Blood Glucose Regulation
Neuromuscular Function
Fatigue Impact Scale
Quality of life

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-18. This information was provided to ClinicalTrials.gov by Applied Science & Performance Institute on 2026-09-17.